Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
391 studies found for:    KRAS
Show Display Options
Rank Status Study
1 Completed KRAS Mutation and Incidence of the Colorectal Carcinoma in Martinique Between 2007 and 2009
Condition: Colorectal Carcinoma
Intervention:
2 Recruiting Technical Optimization of Detection of KRAS, BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Other: KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA
3 Recruiting Detection of KRAS, NRAS et BRAF Mutations in Plasma Circulating DNA From Patients With Metastatic Colorectal Cancer
Condition: Colorectal Cancer Metastatic
Intervention: Genetic: KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA
4 Not yet recruiting A Real World Study to Evaluate Effectiveness of Avastin (Bevacizumab) for First Line Treatment of Patients With Metastatic Colorectal Cancer and Known KRAS Status
Condition: Colorectal Cancer
Interventions: Drug: Anti-EGFR-Containing Regimen;   Drug: Bevacizumab-containing regimen;   Drug: Chemotherapy
5 Recruiting Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
Condition: Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
Interventions: Drug: Sorafenib and irinotecan combination;   Drug: Sorafenib monotherapy;   Drug: Irinotecan monotherapy
6 Completed Comparison of KRAS/BRAF Mutational Status With Conventional Techniques and Plasma Samples Analysis
Condition: Colorectal Cancer
Interventions: Other: Plasma Analysis of circulating cell free DNA;   Other: Tumor tissue analysis of circulating cell free DNA
7 Completed Epidemiologic Study of KRAS Mutation in Brazilian Patients With Advanced or Metastatic Non Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Intervention:
8 Completed Prevalence of the Mutational Status of V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) in Metastatic Colorectal Cancer (mCRC) in Argentine Patients
Condition: Colorectal Neoplasms
Intervention:
9 Completed Comparison of AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients
Condition: Non Small Cell Lung Cancer
Interventions: Drug: AZD6244;   Drug: docetaxel;   Drug: Placebo
10 Completed Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas
Condition: Non-small Cell Lung Cancer Metastatic
Intervention: Biological: CTC
11 Completed Medical Records Review to Describe the Patterns of KRAS Testing and Vectibix Use in Europe
Condition: Metastatic Colorectal Cancer
Intervention: Other: Other
12 Active, not recruiting
Has Results
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Condition: Non Small Cell Lung Carcinoma
Interventions: Drug: AZD6244;   Drug: Erlotinib;   Drug: AZD6244 + Erlotinib
13 Completed Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Irinotecan;   Drug: Panitumumab
14 Completed Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Irinotecan;   Drug: Temsirolimus
15 Withdrawn Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Drug: capecitabine and cetuximab
16 Completed KRAS Wild-type Metastatic Colorectal Cancer Trial
Condition: Colorectal Cancer
Interventions: Drug: Dacogen™ (decitabine);   Drug: Vectibix® (panitumumab)
17 Completed A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer
Conditions: KRAS Positive Patients With Non-small Cell Lung Cancer;   Squamous Cell Non-small Cell Lung Cancer
Intervention: Drug: BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)
18 Not yet recruiting Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.
Conditions: Advanced Non-small Cell Lung Cancer;   KRAS Gene Mutation;   Lung Cancer
Interventions: Drug: Binimetinib;   Drug: Pemetrexed;   Drug: Cisplatin
19 Active, not recruiting RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab
Condition: Colorectal Cancer Metastatic
Intervention: Drug: FOLFIRI + Cetuximab
20 Suspended A Trial of FOLFIRI With MEK162 in Patients With Advanced KRAS Positive Metastatic Colorectal Cancers
Condition: Advanced KRAS Positive Metastatic Colorectal Cancer
Intervention: Drug: MEK162 and FOLFIRI

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.